Open Foundation Models in Healthcare: Challenges, Paradoxes, and Opportunities with GenAI Driven Personalized Prescription
Authors: Mahdi Alkaeed, Sofiat Abioye, Adnan Qayyum, Yosra Magdi Mekki, Ilhem Berrou, Mohamed Abdallah, Ala Al-Fuqaha, Muhammad Bilal, Junaid Qadir
Organizations: Department of Computer Science and Engineering, College of Engineering, Qatar University, Doha, Qatar · Birmingham City University, Birmingham, United Kingdom · College of Science and Engineering, Hamad Bin Khalifa University (HBKU), Doha, Qatar · College of Medicine, Qatar University, Doha, Qatar · University of the West of England (UWE), Bristol, United Kingdom
In response to the success of proprietary Large Language Models (LLMs), there is a growing interest in developing open, non-proprietary LLMs and AI foundation models (AIFMs) for transparent use in academic, scientific, and non-commercial applications. Open models have substantial potential to improve healthcare applications. In this paper, we provide a comprehensive survey and a taxonomy of state-of-the-art open LLMs and AIFMs for clinical tasks. In addition, we empirically evaluate open-weight LLMs on a personalized-prescription task and compare them with a proprietary model with and without Retrieval-Augmented Generation (RAG). Across 100 synthetic patient profiles, the open-weight models matched or exceeded the proprietary baseline on overall suitability accuracy without retrieval augmentation (0.810--0.850 versus 0.780), although the confidence intervals overlap; with retrieval augmentation, every model improved, and the ranking closed to within 0.04. Gains from RAG were field-dependent rather than uniform. To highlight the clinical relevance of LLM-driven personalized prescriptions, we also conduct a subjective evaluation in which two raters, blinded to model and condition, scored responses independently of each other. Their ratings did not follow the accuracy gains: retrieval raised overall suitability accuracy for every model while lowering the two-rater means for two of the four on all five dimensions. Finally, we outline the ethical implications and potential risks associated with the misuse of advanced LLMs and AIFMs, highlighting the importance of responsible and transparent deployment in healthcare contexts. \textit{Data and code used in the paper will be released upon publication.
Figures & tables
Ref.
Type
Domain
Primary Focus
OS
OS FM Tax.
Emp. CS
OS vs. CS
Human
He et al. [ 14 ]
Methodological review
Healthcare
Provides a comprehensive review of healthcare FMs, including multi-modal FMs.
✗
≈
✗
✗
✗
Khan et al. [ 15 ]
Methodological review
Medicine
Provides a taxonomy of FMs in medicine and discusses their challenges
✗
≈
✗
✗
✗
Mahesh et al. [ 16 ]
Review
Healthcare
Explores the adoption of FMs in healthcare along with challenges and ethical considerations.
✗
✗
✗
✗
✗
Li et al. [ 17 ]
Review
Biomedical Healthcare
Surveys FMs with federated learning for biomedical applications.
≈
≈
✗
✗
✗
Zhang et al. [ 18 ]
Survey
Computational healthcare (CH)
Data-centric FMs in CH applications and associated challenges
✗
≈
✗
✗
✗
Bilal et al. [ 19 ]
Survey
Pathology
Overviews applications of FMs in computational pathology
✗
✗
✗
✗
✗
TABLE I: Comparison of related works on foundation models in healthcare with our paper. Legend: OS → Open Source; FMs → Foundation Models; Tax. → Taxonomy; Emp. CS → Empirical Case Study; OS vs. CS → Open-Source vs. Closed-Source benchmarking; Human → human or expert evaluation of model outputs reported; ✓ → covered; ≈→ partially covered; ✗ → not covered.
Fig. 1: Levels of Open-Source Access for LLMs and AIFMs. The figure shows the spectrum from Fully Closed Source to Fully Open Source, detailing key aspects and descriptions for each level. (Adapted from [ 28 ] ).
Fig. 2: Applications of LLMs in Healthcare. This figure shows six key areas: Clinical Documentation, Disease Prediction and Diagnosis, Drug Discovery, Virtual Health Assistants, NLP in EHRs, and Telemedicine Support.
Model (year)
Released params
Ref.
W
license
C
D
OSAID
Biomedical text encoders and generators
BioBERT (2020)
110M, 340M
[ 69 ]
✓
none
≈
✗
✗
BioMegatron (2020)
345M
[ 113 ]
✓
bsp
✓
✗
✗
BioELECTRA (2021)
110M
[ 114 ]
✓
none
✗
✗
✗
KeBioLM (2021)
n/s
[ 115 ]
✓
none
≈
✗
✗
BioBART (2022)
140M, 406M
[ 116 ]
✓
osi
✓
✗
✗
TABLE II: Open AIFMs for healthcare applications. W : weights ( ✓ public, ◗ gated, ✗ not released). license : weight licensing ( osi OSI-approved, ccl community/use-restricted, nc non-commercial, nc-nd non-commercial/no-derivatives, bsp bespoke terms, none none declared, n/a not applicable). C : training code; D : training data; ≈ partial or access-controlled release. OSAID : compliance with the Open Source AI Definition v1.0 [ 37 ] and “n/s” denotes not stated.
Dataset
Modality
Task type
Size
Access
License
Open access
Observed Antibody Space [ 154 ]
Antibody sequences
Protein modeling
1.5B unpaired sequences from 80 studies and paired sequences from 5 studies
> 37B compounds, > 4.5B ready-to-dock 3D compounds
Open
Free-use terms
TABLE III: Publicly documented healthcare datasets used for LLM and AIFM development and evaluation, grouped by access tier. Open : anonymous download. Registered : free account or click-through agreement. Credentialed : identity verification, human-subjects training, and a signed data use agreement. Controlled : approval by a data access committee.
License class
Models
Share
OSI-approved (Apache-2.0, MIT)
16
35.6%
Bespoke terms of use
8
17.8%
Community license (use-restricted)
6
13.3%
Non-commercial
4
8.9%
Non-commercial, no derivatives
4
8.9%
None declared
6
13.3%
TABLE IV: Release openness of the 45 healthcare and healthcare-adjacent foundation models in Table II .
Fig. 3: Illustration of the proposed methodology for evaluating open-weight and proprietary LLMs using two settings, i.e., with and without Retrieval-Augmented Generation (RAG).
Context
You are an experienced and helpful prescribing assistant named Charlie. Charlie can support prescribers to carry out relevant checks when prescribing medication based on the patient’s medical profile and medical knowledge. You should tell if the medication is suitable for the user based on the following patient profile and provide the result in JSON format:
< patient profile >
Instructions
For each check, use “Suitable”, “Risky”, or “N/A”, and provide a reason and evidence field. Cite the source filename and page when retrieved context is supplied. Return an overall result, a score from 0 (clearly unsuitable) to 100 (clearly suitable), and a reason.
TABLE VI: Field-level and overall-suitability performance on 100 synthetic profiles using the first of two runs. P, R, and F1 are macro-averaged. Mean field accuracy is the unweighted mean of the eight field accuracies.
Fig. 4: Two-reviewer mean scores (scale 0–5) for each of the 12 reviewed profiles. Each subplot is one rating dimension; the final panel averages the five dimensions.
Model
Cond.
MSA
DID
PSDA
PSS
GA
GPT-5.6 Luna
RAG
4.83±0.39
4.71±0.45
4.54±0.58
4.58±0.56
4.54±0.58
No RAG
4.67±0.49
4.58±0.47
4.25±0.62
4.46±0.50
4.46±0.50
Llama 4 Scout
RAG
4.75±0.45
4.58±0.47
4.29±0.58
4.54±0.54
4.50±0.52
No RAG
4.92±0.29
4.79±0.33
4.54±0.50
4.67±0.49
4.62±0.43
Mistral Small 3.2 24B Instruct
RAG
4.92±0.29
4.79±0.40
4.58±0.56
4.75±0.45
4.75±0.45
No RAG
5.00±0.00
4.79±0.26
4.46±0.45
4.62±0.48
4.58±0.47
TABLE VII: Mean ± SD of the two-reviewer mean score across 12 patient profiles (scale 0–5; observed scores 3–5). RAG = with Retrieval-Augmented Generation; No RAG = without.
May 5, 2026·Richard A. A. Jonker, Alexander Christiansen, Alexandros Maniatis +4LLM GroundingHealthcare
Aalborg University Business School Fibigerstræde 2, Aalborg East 9220, Denmark · IEETA, DETI, LASI, University of Aveiro Campus Universitário de Santiago, Aveiro 3810-193, Portugal